glp·helper
glphelper.com/semaglutide/california/livermore
GLP-1 receptor agonistFDA-approved December 2017 (Ozempic) · June 2021 (Wegovy)Rx · Subcutaneous injection (weekly) · oral tablet (Rybelsus, daily) · Once weekly (injectable)

Semaglutide® providers &
prescriptions in Livermore, CA

Verified Semaglutide providers in Livermore, CA. Checked against the NPI registry, sorted by waitlist, not by who pays us.[7]

city providers
27
as of today
median wait
8d
first visit
telehealth
71%
of providers
cash range
$25 to $1,150
monthly
§ 02Provider directory: California
28 of 28 shown

Find a Semaglutide provider in California.

Every entry is checked against the NPI registry and the California medical board. Listings are ordered by current waitlist. The provider who can see you fastest appears first. We do not accept payment for placement.

Filter →
Type
Provider
City
Waitlist
Insurance
Browse by California city · /semaglutide/california/{city}
§ 03Getting Semaglutide in Livermore
28 providers · Livermore, CA

How to get Semaglutide in Livermore.

28 GLP-1 prescribers and 7 local resource types are on record for Livermore, plus 3 nearby towns in the directory.

Prescribers in Livermore
28 prescribers
28 GLP-1 prescribers in Livermore, most listed as Internal Medicine (13), Family Medicine (12) and Internal Medicine, Endocrinology, Diabetes & Metabolism (1). Any California-licensed physician, nurse practitioner, or PA can prescribe Semaglutide, over video or in person. The nearest towns on record are Pleasanton (39 providers), Dublin (30 providers) and San Ramon (33 providers).
Around the prescription in Livermore
7 listed nearby
25 dietitians, 2 nutritionists, 6 gyms, 6 fitness clubs, 6 trainers, 5 physiotherapists and 6 places to move are on record near Livermore.
Medicaid (weight loss)
Diabetes only
As of April 2026, California Medicaid covers GLP-1s for diabetes but not for weight loss. Employer and private plans can still cover them; that is a plan-design choice, not a state rule.

Medicaid status above is for weight-loss use and was compiled April 2026 from KFF and public Medicaid trackers; only 13 states cover it and several are mid-change, so confirm California’s current Medicaid and plan rules before booking. GLPHelper provides information and provider matching, not medical or coverage advice.

§ 04Medication factsheet
cited · last review 2026.05.19

The molecule in Ozempic, Rybelsus, and Wegovy. The brands differ in approved use and maximum dose.

Semaglutide is a once-weekly GLP-1 receptor agonist sold under three brand names by Novo Nordisk: Ozempic and Rybelsus for type 2 diabetes, and Wegovy for chronic weight management. It mimics a gut hormone that signals satiety to the brain and slows gastric emptying. The injectable forms share the same molecule; only the approved indication and maximum dose differ.[2][3]

In the STEP-1 obesity trial, adults without diabetes taking Wegovy (semaglutide 2.4 mg) lost a mean of 14.9% of body weight at 68 weeks versus 2.4% with placebo. In the SELECT trial, semaglutide 2.4 mg reduced major adverse cardiovascular events by 20% in adults with overweight or obesity and established cardiovascular disease but without diabetes.[1]

At a glanceMultiple (brand-specific)
Generic name
semaglutide
Drug class
GLP-1 receptor agonist
Manufacturer
Novo Nordisk
FDA approved
December 2017 (Ozempic) · June 2021 (Wegovy)
Approved use
Type 2 diabetes (Ozempic/Rybelsus) · chronic weight management (Wegovy)
Off-label use
Use outside the approved brand/indication is off-label
Administration
Subcutaneous injection (weekly) · oral tablet (Rybelsus, daily) · Once weekly (injectable)
Available doses
0.25 mg · 0.5 mg · 1 mg · 1.7 mg · 2.4 mg
Half-life
≈ 7 days
Pregnancy
Discontinue ≥ 2 months before a planned pregnancy

Community health · CDC

Weight & metabolic health in Livermore

Livermore, California has a population of 87,955 people. The adult obesity rate in Livermore is an age-adjusted estimate of 23%, 6.1 percentage points below the California state rate of 29.1%. Diagnosed diabetes reaches 7.9% of adults in Livermore. Inactivity, meaning no leisure-time physical activity reported in the past month, affects 16.3% of adults in Livermore.

of Livermore adults have obesity
23%
diagnosed diabetes
7.9%
no regular physical activity
16.3%

Age-adjusted estimates for Livermore, community figures, not individual risk. CDC PLACES, 2025 release.

Estimate your weight lossOzempic side effects in men
§ 05Support around Semaglutide in Livermore
6 fitness clubs

The prescription is one part. Here is the rest, in Livermore.

Trials of semaglutide paired the drug with diet counseling and regular activity. Every name below is a real listing near Livermore, CA, ordered as the registry lists them, never by who pays us.

Fitness clubs and recreation centers

Fitness clubs and recreation centers run classes and pools, an easier start than a weight room.

Joya Livermore
FITNESS
4.8 on Google · 92 reviews
1923 Second St
Website
Anywhere Warrior
FITNESS
4.9 on Google · 46 reviews
51 Wright Brothers Ave Ste G
Website
Arena Training Center
BOXING
4.9 on Google · 28 reviews
4555 Las Positas Rd Unit e
Website
Vertica Fitness Livermore
FITNESS
5.0 on Google · 12 reviews
2480 Nissen Dr
Website
Anytime Fitness
GYM
4.8 on Google · 687 reviews
1855 Holmes St
Website
Fitness 19
GYM
4.5 on Google · 544 reviews
1456 Railroad Ave
Website

Registered dietitians

A registered dietitian builds the food plan around your prescription. Call to ask about GLP-1 nutrition plans and insurance.

Kimberly Ancira, MS, RDN
RD
Registered dietitian
366 Acorn Pl
Call 925-784-9317NPI 1245837608
Karen Buntjer, R.D., C.D.E
RD
Registered dietitian
5725 W Las Positas Blvd
Call 925-416-6730NPI 1598978132
Maria Teresa Carena
RD
Registered dietitian
3801 Miranda Ave
Call 650-493-5000NPI 1952575474
Rachel Connors, R.D
RD
Registered dietitian
7011 East Ave
Call 925-294-3783NPI 1366798407
Noel Dibish, RD
RD
Registered dietitian · Pediatric
27400 Hesperian Blvd
Call 510-784-4954NPI 1093871857
Insuk Durham, R.D
RD
Registered dietitian
4951 Arroyo Rd
Call 925-373-4700NPI 1023021979
§ 06Clinical evidence
STEP 1 to 4 + SELECT (N = 17,604)

What the trials actually showed.

We summarize the STEP weight-management program, the SUSTAIN diabetes program, and the SELECT cardiovascular outcomes trial. Figures are means at each trial's primary endpoint.

STEP-1 randomized 1,961 adults with overweight or obesity (without diabetes) to semaglutide 2.4 mg or placebo for 68 weeks. Mean weight change was −14.9% with semaglutide versus −2.4% with placebo; 86% of treated patients lost ≥5% of body weight.[2]
STEP / SELECT endpoint table2.4 mg / 68 wk
Mean weight change (Wegovy 2.4 mg)
−14.9%
STEP-1, 68 wk vs −2.4% placebo[2]
Patients losing ≥5% body weight
86%
STEP-1, 2.4 mg[2]
Major adverse cardiac events
−20%
SELECT, HR 0.80[3]
HbA1c reduction (T2D)
−1.4 to −1.8%
SUSTAIN program[4]
Effect size varies with baseline characteristics and adherence. Individual response may differ materially.
average semaglutide weight loss →mapped to your starting weight
§ 07Safety & adverse events
from FDA label, sect. 6.1

Most side effects are gastrointestinal and resolve within weeks.

The most common adverse events in STEP trials were nausea (44%), diarrhea (30%), and vomiting (24%), more frequent at the 2.4 mg dose than at Ozempic doses, but typically transient.[1] Serious events were rare but include pancreatitis, gallbladder disease, and an FDA boxed warning regarding thyroid C-cell tumors based on rodent data.[8]

Boxed warning. Boxed warning: risk of thyroid C-cell tumors. Contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN-2).
Effect
Frequency
Severity
Note
Nausea
20 to 44%
mild
Most common; dose-dependent, usually eases after titration
Diarrhea
20 to 30%
mild
More frequent during dose escalation
Vomiting
16 to 24%
mild
Reduced by slower titration
Constipation
20 to 24%
mild
Abdominal pain
10%
moderate
Pancreatitis
<0.3%
serious
Discontinue if acute pancreatitis is suspected
Gallbladder disease
1.6 to 2.6%
serious
Cholelithiasis risk rises with rapid weight loss
Thyroid C-cell tumors
rodent data
boxed warning
Contraindicated with MTC or MEN-2 history
§ 08Cost & coverage, published, not gated
USD · monthly

Most directories hide the price. We don't.

Cash prices vary roughly 50× between the brand-name retail rate and a manufacturer savings card. The number you actually pay depends on your insurance plan, your diagnosis code, and which pharmacy fills the script. Here are the ranges, plainly.

Data sources: GoodRx national retail survey[6], CMS Part D formulary files[5], Novo Nordisk patient access program.

Cash, Wegovy (no insurance)
$1,300 to $1,400
per month
Brand-name retail average[6]
Cash, Ozempic (no insurance)
$950 to $1,150
per month
Brand-name retail average[6]
Commercial insurance (T2D)
$25 to $250
per month copay
Usually covered for diabetes with prior authorization
Commercial insurance (weight)
Often denied
Wegovy is on-label but frequently requires PA and is denied
Medicare Part D
$0 to $100
per month
T2D covered; weight-loss indication not covered by law[5]
Manufacturer savings card
as low as $0 to $25
per month
Commercial insurance only; eligibility limits apply
Updated weekly · last fetch 2026-05-18 04:00 UTCCost methodology →
Find Semaglutide providers in California

NPI-verified Semaglutide (semaglutide) prescribers and clinics, ordered by availability, never by who pays us.

Semaglutide in other states

Find NPI-verified Semaglutide (semaglutide) doctors, clinics, and pharmacies in the states we cover, ordered by availability, never by who pays us.

Related GLP-1 research
§ 09Frequently asked: Semaglutide in California

The questions people ask before they book.

Answers reviewed by the GLPHelper Medical Team. Citations link to primary sources, never marketing copy.

Yes. Semaglutide is the active molecule in all three Novo Nordisk products. Ozempic and Rybelsus are approved for type 2 diabetes; Wegovy is approved for chronic weight management at a higher maximum dose (2.4 mg/week). Insurers treat the brands as separate drugs.[1]